Penn Vet | Clinical Trial Detail - Use of a newly available glargine (Semglee®) for treatment of diabetes mellitus in cats
Contact
New Bolton Center Kennett Square, PA
Emergencies & Appointments:
610-444-5800
Directions
Ryan Hospital Philadelphia, PA
Emergencies:
215-746-8911
Appointments:
215-746-8387
Directions

Use of a newly available glargine (Semglee®) for treatment of diabetes mellitus in cats

Nov 7, 2022

Description: Well-regulated diabetic cats, treated with glargine, will be switched to Semglee. The FreeStyle Libre glucose monitoring system will help determine if Semglee is as effective as glargine in regulating diabetes in cats.

Requirements: For this free to the owner study, cats with diabetes will be required to visit the hospital 4 times over the 56-day study period and will have a free FreeStyle Libre glucose monitor placed for the first 2 weeks. Owners will have to scan the glucose monitor every 8 hours at home and administer (freely provided) Semglee instead of glargine, at the same dose and frequency.

Contact: For more information about participating in the study please contact us by emailing vcic@vet.upenn.edu or calling 215-573-0302.

Institutional approval: POAP #648, IACUC # 807324